Security key
29337E102
Enliven Therapeutics, Inc. - COMMON STOCK (ELVN)
CUSIP: 29337E102
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 396,085
- Total 13F value
- $20,100,465
- Share change
- +344,024
- SEC-reported price per share
- $50.75
- Number of holders
- 8
- Value change
- +$17,458,370
- Number of buys
- 6
- Shares outstanding
- 71,310,600
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
8
Top holders
8
ELVN full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Enliven Therapeutics, Inc. SEC filings
Enliven Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29337E102
Recent filing periods:
Ownership snapshot
Top reported holders of ELVN - Enliven Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
22 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 13%
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 13%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
13%
ORBIMED ADVISORS LLC
9.5%
Polar Capital Holdings Plc
8.5%
Commodore Capital LP
7.7%
Vestal Point Capital, LP
5.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
Company
|
13%
from 13D/G
|
$267,706,443
6,829,246 shares
|
— | 31 Mar 2026 |
| ORBIMED ADVISORS LLC |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
9.5%
from 13D/G
|
$312,013,890
7,959,538 shares
|
— | 31 Mar 2026 |
| Polar Capital Holdings Plc |
13D/G
13F
Company
|
8.5%
|
$200,401,261
5,056,807 shares
|
+$99,864,667 | 31 Mar 2026 |
| Commodore Capital LP |
13D/G
3/4/5
13F
10%+ Owner · Company
|
7.7%
|
$217,578,601
4,800,940 shares
|
-$55,381,810 | 31 Mar 2026 |
| Vestal Point Capital, LP |
13D/G
13F
Company
|
5.4%
|
$147,290,000
3,250,000 shares
|
-$26,285,600 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.1%
from 13D/G
|
$144,440,514
3,684,707 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
8
Shares
396,085
Rows available
8
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
168
Q2 2026 holders
8
Holder diff
-160
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend